Leerink Partnrs Issues Optimistic Estimate for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2027 earnings per share estimates for Elanco Animal Health in a research note issued to investors on Thursday, July 17th. Leerink Partnrs analyst D. Clark now anticipates that the company will earn $1.11 per share for the year, up from their previous forecast of $1.07. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's FY2028 earnings at $1.29 EPS.

ELAN has been the subject of several other research reports. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a research report on Thursday, July 17th. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Stifel Nicolaus upped their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Finally, UBS Group upped their target price on Elanco Animal Health from $17.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $16.17.

Elanco Animal Health Trading Down 2.2%

ELAN stock traded down $0.33 during midday trading on Monday, hitting $14.70. The company had a trading volume of 6,504,043 shares, compared to its average volume of 4,061,038. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $15.78. The stock's 50 day moving average price is $13.94 and its 200 day moving average price is $11.85. The stock has a market cap of $7.30 billion, a price-to-earnings ratio of 19.86, a PEG ratio of 2.93 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company posted $0.34 earnings per share. The business's revenue was down 1.0% on a year-over-year basis.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in shares of Elanco Animal Health by 6.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after acquiring an additional 1,074,274 shares in the last quarter. Yousif Capital Management LLC bought a new position in Elanco Animal Health in the first quarter worth $119,000. Wealth Enhancement Advisory Services LLC bought a new position in Elanco Animal Health in the first quarter worth $111,000. Cinctive Capital Management LP bought a new position in Elanco Animal Health in the fourth quarter worth $627,000. Finally, SG Americas Securities LLC bought a new position in Elanco Animal Health in the first quarter worth $891,000. Institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.